BRKRP

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Bruker (NASDAQ:BRKR) and the rest of the research tools & consumables stocks fared in Q1.

Bruker Corporation recently commissioned its BioSpec 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, enabling ultra-high-resolution MRI and MRSI for advanced cancer and neuroscience research in preclinical models. This system’s ability to probe tissue microstructure and localized metabolism in vivo highlights how Bruker’s high-end imaging platforms are becoming embedded in cutting-edge translational oncology and brain...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Why Bruker (BRKR) is on investors’ radar today Bruker (BRKR) has drawn attention after a recent move in its share price, with the stock last closing at US$43.27. That puts fresh focus on how its current valuation lines up with fundamentals. See our latest analysis for Bruker. That latest move comes after a 18.91% 7 day share price return and a 15.11% 30 day share price return, although the share price is still down 10.06% year to date and the 3 year total shareholder return of 39.54% and 5...

In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains.

Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.

2026-05-06. The following slide deck was published by Bruker Corporation in conjunction with their 2026 Q1 earnings call.

Bruker Corporation (BRKR) Q1 2026 Earnings Call May 6, 2026 8:00 AM EDTCompany ParticipantsJoe KostkaFrank Laukien - Chairman, CEO & PresidentGerald...

Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that management said came in “well ahead of expectations,” even as the company continued to face pressure from U.S. academic demand weakness as well as tariff and currency headwinds. President and CEO Frank Laukien told investors that while y

Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that management said came in “well ahead of expectations,” even as the company continued to face pressure from U.S. academic demand weakness as well as tariff and currency headwinds. President and CEO Frank Laukien told investors that while y

Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Preclinical Imaging Industry Analysis, Size, Share, Growth, Trends, and Forecast 2026-2033 - (by Product Type, Application, End-User, Geographic Coverage and by Company)" has been added to ResearchAndMarkets.com's offering. The global Preclinical Imaging Market is poised for robust growth, with market revenue projected to increase from $1.1 billion in 2026 to $1.7 billion by 2033, reflecting a CAGR of 6.10% during the forecast period. The expansion o

Bruker (BRKR) delivered earnings and revenue surprises of +33.62% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bruker (BRKR) delivered earnings and revenue surprises of +33.62% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Scientific instrument company Bruker (NASDAQ:BRKR). announced better-than-expected revenue in Q1 CY2026, with sales up 2.7% year on year to $823.4 million. The company expects the full year’s revenue to be around $3.59 billion, close to analysts’ estimates. Its non-GAAP profit of $0.31 per share was 34.8% above analysts’ consensus estimates.

Bruker recently saw its shares weaken further as investors weighed an upcoming Q1 earnings report and fresh insider selling activity against current valuation metrics suggesting the stock is trading below one estimate of intrinsic value. The combination of flat year-on-year revenue expectations, past revenue guidance that exceeded forecasts despite an EPS miss, and a gap to intrinsic value estimates is sharpening focus on whether the forthcoming results can shift sentiment. With analysts...

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A few weeks ago, a research paper out of MIT (the college) crossed my desk that most investors would have ignored.It was about worms. Specifically, it was about a team that had successfully mapped the entire brain of a microscopic worm — every neuron, every connection. Then it laid out what it would take to scale that process from a worm… to a mouse… and eventually, to a human.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, here’s where things get interesting for us. For deca

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 5%.